Latest Action
Subcommittee Hearings Held.
5/21/2019 • House
Summary
Drug Price Transparency Act
This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
Introduced in House • 4/4/2019
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (2)
Party Breakdown
Sponsor
Cosponsors (1)
Bill Journey
Originated in the House
Introduced
April 4, 2019
Committee Review
May 21, 2019
Subcommittee Hearings Held.
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (1)
Related Bills (6)
H.R. 19
Lower Costs, More Cures Act of 2019
H.R. 2113
Prescription Drug STAR Act
H.R. 2296
More Efficient Tools to Realize Information for Consumers Act
S. 2051
Strengthening Average Sales Price Reporting Act of 2019
S. 3129
Lower Costs, More Cures Act of 2019
H.R. 1570
Removing Barriers to Colorectal Cancer Screening Act of 2020